Table 1.
Clinical characteristics of 223 pancreatic adenocarcinoma patients involved in the study.
| Characteristics | All (N = 223) | Detailed data | ||
|---|---|---|---|---|
| Training cohort (N = 107) | Validation cohort (N = 70) | Fudan cohort (N = 46) | ||
| Age at diagnosis, years | ||||
| ≤ 60 | 77 (34.53%) | 35 (15.70%) | 19 (8.52%) | 23 (10.31%) |
| ≥60 | 146 (65.47%) | 72 (32.29%) | 51 (22.87%) | 23 (10.31%) |
| Gender | ||||
| Female | 101 (45.29%) | 50 (22.42%) | 30 (13.45%) | 21 (9.42%) |
| Male | 122 (54.71%) | 57 (25.56%) | 40 (17.94%) | 25 (11.21%) |
| MSI status | ||||
| MSI-I | 28 (15.82%) | 14 (7.91%) | 14 (7.91%) | – |
| MSI-L | 9 (5.08%) | 2 (1.13%) | 7 (3.95%) | – |
| MSS | 140 (79.10%) | 91 (51.41%) | 49 (27.68%) | – |
| Histologic grade | ||||
| G1 | 30 (17.14%) | 22 (12.57%) | 8 (4.57%) | – |
| G2 | 95 (54.29%) | 55 (31.43%) | 40 (22.86%) | – |
| G3 | 48 (27.43%) | 28 (16%) | 20 (11.43%) | – |
| G4 | 2 (1.14%) | 1 (0.57%) | 1 (0.57%) | – |
| TNM stage | ||||
| I | 31 (14.22%) | 12 (5.50%) | 9 (4.13%) | 10 (4.59%) |
| II | 166 (76.15%) | 88 (40.37%) | 57 (26.15%) | 21 (9.63%) |
| III | 15 (6.88%) | 2 (0.92%) | 2 (0.92%) | 11 (5.05%) |
| IV | 6 (2.75%) | 4 (1.83%) | 1 (0.46%) | 1 (0.46%) |
MSI, Microsatellite instability; MSS, Microsatellite stable; MSI-I, MSI-indeterminate; MSI-L, MSI-low; TNM, Tumor node metastasis.